Minthon, Lennart

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 1,700

Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins

Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L. F., Galasko, D. R., Jutel, M., Karydas, A., et al. (2007) · Nature Medicine

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 1,048

Cerebrospinal Fluid β-Amyloid(1-42) in Alzheimer Disease: Differences Between Early- and Late-Onset Alzheimer Disease and Stability During the Course of Disease

Andreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (1999) · Archives of Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 660

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study

Visser, P. J., Verhey, F., Knol, D. L., Scheltens, P., Wahlund, L.-O., Freund-Levi, Y., Tsolaki, M., Minthon, L., Wallin, Å. K., Hampel, H., et al. (2009) · The Lancet Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 614

Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice

Andreasen, N., Minthon, L., Davidsson, P., Vanmechelen, E., Vanderstichele, H., Winblad, B., & Blennow, K. (2001) · Archives of Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 573

Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity

Lindqvist, D., Janelidze, S., Hagell, P., Erhardt, S., Samuelsson, M., Minthon, L., Hansson, O., Björkqvist, M., Träskman-Bendz, L., & Brundin, L. (2009) · Biological Psychiatry

Tryptophan and brain disordersSuicide and Self-Harm Studies

Cited by 524

Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders

Hall, S., Öhrfelt, A., Constantinescu, R., Andreasson, U., Surova, Y., Bostrom, F., Nilsson, C., Widner, H., Decraemer, H., Nägga, K., et al. (2012) · Archives of Neurology

Dementia and Cognitive Impairment ResearchParkinson's Disease Mechanisms and Treatments

Cited by 473

CSF A β 42/A β 40 and A β 42/A β 38 ratios: better diagnostic markers of Alzheimer disease

Janelidze, S., Zetterberg, H., Mattsson, N., Palmqvist, S., Vanderstichele, H., Lindberg, O., van Westen, D., Stomrud, E., Minthon, L., Blennow, K., et al. (2016) · Annals of Clinical and Translational Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 456

Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid β-Amyloid 42: A Cross-Validation Study Against Amyloid Positron Emission Tomography

Palmqvist, S., Zetterberg, H., Blennow, K., Vestberg, S., Andreasson, U., Brooks, D. J., Owenius, R., Hägerström, D., Wollmer, P., Minthon, L., et al. (2014) · JAMA Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 368

Standardization of measurement of β-amyloid(1-42)in cerebrospinal fluid and plasma

Vanderstichele, H., Kerschaver, E. V., Hesse, C., Davidsson, P., Buyse, M.-A., Andreasen, N., Minthon, L., Wallin, A., Blennow, K., & Vanmechelen, E. (2000) · Amyloid

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 301

SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease

Brinkmalm, A., Brinkmalm, G., Honer, W. G., Frölich, L., Hausner, L., Minthon, L., Hansson, O., Wallin, A., Zetterberg, H., Blennow, K., et al. (2014) · Molecular Neurodegeneration

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 293

CCL2 Is Associated with a Faster Rate of Cognitive Decline during Early Stages of Alzheimer's Disease

Westin, K., Buchhave, P., Nielsen, H., Minthon, L., Janciauskiene, S., & Hansson, O. (2012) · PLoS ONE

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 277

Genome-wide association study identifies four novel loci associated with Alzheimer’s endophenotypes and disease modifiers

(ADNI), A. D. N. I., Deming, Y., The Alzheimer Disease Genetic Consortium (ADGC), Li, Z., Kapoor, M., Harari, O., Del-Aguila, J. L., Black, K., Carrell, D., Cai, Y., et al. (2017) · Acta Neuropathologica

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 231

Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease

Zetterberg, H., Andreasson, U., Hansson, O., Wu, G., Sankaranarayanan, S., Andersson, M. E., Buchhave, P., Londos, E., Umek, R. M., Minthon, L., et al. (2008) · Archives of Neurology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 224

Cerebral pattern of pro- and anti-inflammatory cytokines in dementias

Tarkowski, E., Liljeroth, A.-M., Minthon, L., Tarkowski, A., Wallin, A., & Blennow, K. (2003) · Brain Research Bulletin

Neuroinflammation and Neurodegeneration MechanismsAlzheimer's disease research and treatments

Cited by 219

Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease

Thorsell, A., Bjerke, M., Gobom, J., Brunhage, E., Vanmechelen, E., Andreasen, N., Hansson, O., Minthon, L., Zetterberg, H., & Blennow, K. (2010) · Brain Research

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 204

Longitudinal stability of CSF biomarkers in Alzheimer's disease

Blennow, K., Zetterberg, H., Minthon, L., Lannfelt, L., Strid, S., Annas, P., Basun, H., & Andreasen, N. (2007) · Neuroscience Letters

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 193

Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD

Sjögren, M., Rosengren, L., Minthon, L., Davidsson, P., Blennow, K., & Wallin, A. (2000) · Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 181

Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer’s disease patients and controls

Martínez-Morillo, E., Hansson, O., Atagi, Y., Bu, G., Minthon, L., Diamandis, E. P., & Nielsen, H. M. (2014) · Acta Neuropathologica

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 168

Low CSF Levels of Both α-Synuclein and the α-Synuclein Cleaving Enzyme Neurosin in Patients with Synucleinopathy

Wennström, M., Surova, Y., Hall, S., Nilsson, C., Minthon, L., Boström, F., Hansson, O., & Nielsen, H. M. (2013) · PLoS ONE

Parkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatments

Cited by 141

Injury markers predict time to dementia in subjects with MCI and amyloid pathology

van Rossum, I. A., Vos, S. J. B., Burns, L., Knol, D. L., Scheltens, P., Soininen, H., Wahlund, L.-O., Hampel, H., Tsolaki, M., Minthon, L., et al. (2012) · Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 136

Evaluation of a Previously Suggested Plasma Biomarker Panel to Identify Alzheimer's Disease

Björkqvist, M., Ohlsson, M., Minthon, L., & Hansson, O. (2012) · PLoS ONE

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 135

Sex-specific genetic predictors of Alzheimer’s disease biomarkers

(ADNI), A. D. N. I., Deming, Y., The Alzheimer Disease Genetics Consortium (ADGC), Dumitrescu, L., Barnes, L. L., Thambisetty, M., Kunkle, B., Gifford, K. A., Bush, W. S., Chibnik, L. B., et al. (2018) · Acta Neuropathologica

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 110

Aβ40 Oligomers Identified as a Potential Biomarker for the Diagnosis of Alzheimer's Disease

Gao, C. M., Yam, A. Y., Wang, X., Magdangal, E., Salisbury, C., Peretz, D., Zuckermann, R. N., Connolly, M. D., Hansson, O., Minthon, L., et al. (2010) · PLoS ONE

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 105